This Autumn, TMC is launching a study to establish a connection between high quality subspecialist reporting of HRCT cases and reduced cost and/or QALYs (Quality Adjusted Life Years) for patients with a specific type of lethal lung fibrosis.
Together, we will look specifically at the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), since this is a particularly unpleasant disease which is often very difficult to diagnose.
TMC believes that high quality subspecialist reporting can not only contribute to better patient care but also reduce longer term costs for the healthcare systems themselves by ensuring that patients get the best care as early as possible.
TMC’s own group of highly subspecalised radiologists will partner on this project with a small number of Swedish lung medicine specialists to enable them to analyse high volumes of these cases.
We’ll keep you up to date with our findings and update you later in the year once the results are in.